Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company benefits from the high demand for GLP-1 peptide drugs, leading to sustained high growth in performance [2][3] - The company is one of the few domestic leaders focusing on peptide drugs, with a strong growth trend expected to continue into 2025 [3] - The company has established numerous strategic partnerships, enhancing its customer resource base [4] Financial Performance - In 2024, the company achieved revenue of 1.625 billion yuan, a year-on-year increase of 57.21%, and a net profit attributable to shareholders of 404 million yuan, up 148.19% [1] - For Q1 2025, the company reported revenue of 566 million yuan, a growth of 58.96%, and a net profit of 153 million yuan, an increase of 130.10% [1] - The company's gross margin improved to 67.78% in 2024, up 6.81 percentage points year-on-year [4] Business Segmentation - Revenue from self-selected products in 2024 was 1.129 billion yuan, growing by 79.49%, while customized products and technical services generated 494 million yuan, up 22.34% [4] - The CDMO/CMO segment generated 473 million yuan, while raw materials and intermediates accounted for 944 million yuan in revenue [4] - The company’s international sales reached 1.026 billion yuan in 2024, a significant increase of 129.10% year-on-year [4] Capacity and Production - The company has modern production bases in Lianyungang and Jiande, with a total capacity of 1.47 million liters [6] - The new 601 workshop for large-scale peptide production has commenced operations, with an expected capacity of 5 tons per year [6] - The company has passed international quality certifications, including EU GMP and US FDA inspections, enhancing its production credibility [6] Profit Forecast - Revenue projections for 2025-2027 are 2.175 billion yuan, 2.768 billion yuan, and 3.424 billion yuan, respectively, with net profits of 562 million yuan, 740 million yuan, and 936 million yuan [8] - The expected EPS for 2025 is 2.56 yuan, with corresponding P/E ratios of 21.36 times [8]

Report Summary 1. Report Industry Investment Rating No industry investment rating is provided in the report. 2. Core Viewpoints - In March, the total bond custody scale increased by 265.56 billion yuan month - on - month, with the increment mainly contributed by inter - bank certificates of deposit (CDs), which reached a record high of 1.12 trillion yuan. However, the custody increments of various interest - rate bonds and credit bonds decreased slightly compared to the previous month [4][7]. - After a mid - to - early - month correction, the bond market recovered in late March. Due to looser funds, the demand for CDs from broad - based funds soared, leading to a significant increase in net financing of CDs despite a high maturity volume, and CD rates peaked and declined. The increased purchases of interest - rate bonds by trading institutions such as broad - based funds and securities firms, along with a marginal decrease in government bond supply, alleviated the pressure on commercial banks' asset - side to undertake primary issuance, and thus eased their liability pressure. However, the demand for credit bonds from trading desks remained weak, the bond purchases by insurance companies slightly decreased, and overseas institutions also significantly increased their CD holdings, with the overall bond purchase volume reaching a new high since August last year [4][9]. - In March, the repo balance increased significantly, and the bond market leverage ratio rose by 0.6 pct month - on - month to 106.8%. Although the increase was similar to the historical average for the same period, it remained at a low level since 2022. By institution, the leverage ratios of commercial banks and non - bank institutions both increased but were still at relatively low levels [4][38]. 3. Summary by Directory 3.1. Inter - bank CD Supply Surge Drove a 2.7 - Trillion - Yuan Increase in March Bond Custody Volume - The total bond custody scale in March increased by 265.56 billion yuan month - on - month, with the increment mainly from inter - bank CDs, reaching 1.12 trillion yuan. The custody increments of other interest - rate bonds and credit bonds decreased slightly. For interest - rate bonds, the net financing and net payment of treasury bonds increased, but the custody increment decreased slightly; the custody increment of local bonds decreased as the issuance of replacement bonds slowed; and the custody increment of policy - bank bonds decreased due to an increase in the maturity volume. For credit bonds, the custody increments of medium - term notes and short - term commercial paper decreased, and the custody scales of enterprise bonds and PPNs continued to decline [7]. - The commercial bank bond custody volume decreased by 53 billion yuan from an increase of 120 billion yuan in the previous month, while the non - bank bond custody increment increased by 338 billion yuan to 448 billion yuan. The custody scale decline of credit - asset - backed securities narrowed to 130 billion yuan. The issuance scale of inter - bank CDs in March reached a record high, with the custody increment rising by 634.4 billion yuan to 1.115 trillion yuan, which was the main reason for the increase in March's custody increment [7]. 3.2. In March, Trading Desks Massively Increased Holdings of Inter - bank CDs and Interest - Rate Bonds, Significantly Easing Commercial Banks' Liability Pressure - **Broad - based Funds**: The custody increment of broad - based funds increased significantly by 158.5 billion yuan to 170.5 billion yuan. They increased their holdings of inter - bank CDs, government bonds, local bonds, and policy - bank bonds, and reduced their holdings of credit bonds and commercial bank bonds. Relative to the stock, they increased their allocation of bonds, mainly inter - bank CDs and various interest - rate bonds [13]. - **Securities Firms**: The bond custody scale of securities firms increased by 1.145 billion yuan from a decrease of 560 million yuan in the previous month, mainly by increasing their holdings of treasury bonds. Relative to the stock, they also increased their allocation of bonds, mainly treasury bonds [17]. - **Insurance Companies**: The bond custody increment of insurance companies slightly decreased by 1.48 billion yuan to 9.64 billion yuan. They reduced their holdings of medium - term notes and increased their holdings of local bonds, among others. Relative to the stock, their bond - allocation strength weakened slightly [20]. - **Overseas Institutions**: The bond custody increment of overseas institutions increased by 7.19 billion yuan to 14.18 billion yuan, reaching a new high since August last year. They significantly increased their holdings of inter - bank CDs and increased their holdings of treasury bonds but reduced their holdings of policy - bank bonds. Relative to the stock, they increased their bond - allocation strength [26]. - **Other Institutions**: The bond custody increment of other institutions decreased from an increase of 60.18 billion yuan in the previous month to a decrease of 990 million yuan, mainly affected by the reduction in the net investment of central bank's outright reverse repurchase. They reduced their holdings of local bonds, policy - bank bonds, and treasury bonds and also reduced their holdings of inter - bank CDs, medium - term notes, and short - term commercial paper. Relative to the stock, they reduced their bond allocation [28]. - **Commercial Banks**: The bond custody scale of commercial banks increased by 58.17 billion yuan, with a decrease of 83.66 billion yuan compared to the previous month. They significantly reduced their holdings of inter - bank CDs, and also reduced their holdings of policy - bank bonds, short - term commercial paper, and commercial bank bonds. Relative to the stock, they reduced their bond allocation [31]. - **Credit Unions**: The bond custody volume of credit unions decreased from an increase of 8.67 billion yuan in the previous month to a decrease of 1.9 billion yuan, mainly due to a large - scale reduction in inter - bank CD holdings. Relative to the stock, they reduced their bond allocation [34]. 3.3. In March, the Bond Market Leverage Ratio Seasonally Rebounded but Remained at a Low Level Since 2022 - In March, the repo balance increased significantly, and the bond market leverage ratio rose by 0.6 pct month - on - month to 106.8%. The increase was similar to the historical average for the same period but remained at a low level since 2022. By institution, the leverage ratio of commercial banks rose by 0.6 pct to 103.2%, only higher than that in January - February this year; the non - bank institution leverage ratio rose by 0.5 pct to 115.9%, still at a relatively low level since April 2022. Among non - bank institutions, the leverage ratios of securities firms and non - legal - person products increased to 200.7% and 114.4% respectively, remaining near historical lows [38]. - In broad - based funds, the repo balances of various institutions rebounded. The repo balances of money market funds and wealth management products increased significantly but were still near historical lows. The repo balances of insurance companies and other products with relatively stable liabilities were close to the high in January this year, and the repo balance of non - money market products of fund companies was relatively stable, still below the pre - March 2023 level [38].

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company benefits from the high demand for GLP-1 peptide drugs, leading to sustained high growth in performance [2][3] - The company is one of the few domestic leaders focusing on peptide drugs, with a strong growth trend expected to continue into 2025 [3] - The company has established numerous strategic partnerships, enhancing its customer resource base [4] Financial Performance - In 2024, the company achieved revenue of 1.625 billion yuan, a year-on-year increase of 57.21%, and a net profit attributable to shareholders of 404 million yuan, up 148.19% [1] - For Q1 2025, the company reported revenue of 566 million yuan, a growth of 58.96%, and a net profit of 153 million yuan, an increase of 130.10% [1] - The company's gross margin improved to 67.78% in 2024, up 6.81 percentage points year-on-year [4] Business Segmentation - Revenue from self-selected products in 2024 was 1.129 billion yuan, growing by 79.49%, while customized products and technical services generated 494 million yuan, up 22.34% [4] - The CDMO/CMO segment generated 473 million yuan, while raw materials and intermediates brought in 944 million yuan [4] - Domestic revenue reached 597 million yuan, a 2.05% increase, while international revenue soared to 1.026 billion yuan, up 129.10% [4] Capacity and Production - The company has modern production bases in Lianyungang and Jiande, with a total capacity of 1.47 million liters [6] - The new 601 workshop for large-scale peptide production has been put into operation, with an expected capacity of 5 tons per year [6] - The company has passed international quality certifications, including EU GMP and US FDA inspections, enhancing its production credibility [6] Profitability Forecast - The company is projected to achieve revenues of 2.175 billion yuan, 2.768 billion yuan, and 3.424 billion yuan for 2025, 2026, and 2027 respectively, with net profits of 562 million yuan, 740 million yuan, and 936 million yuan [8] - The expected EPS for 2025, 2026, and 2027 is 2.56 yuan, 3.37 yuan, and 4.26 yuan respectively, with corresponding P/E ratios of 21.36, 16.21, and 12.81 [8]

Investment Rating - The investment rating for the electronics industry is "Positive" [2] Core Insights - The electronics industry has an allocation ratio of 18.7%, maintaining the highest position in the market, with an overweight ratio of 7.3% [10][16] - In the semiconductor sector, institutions have significantly increased their holdings in SMIC Hong Kong, emphasizing the theme of self-sufficiency [22] - The consumer electronics sector is expected to benefit from national subsidy policies, which will stimulate demand for electronic products [31] - The components sector shows strong demand certainty driven by AI, with quality companies in the supply chain gradually increasing their performance [3][31] - The optical and optoelectronic sector has seen price increases for panels despite being in the off-season, supported by strong demand [3] - The electronic chemicals sector continues to see an increase in holdings due to ongoing domestic substitution efforts [3] Summary by Sections Semiconductor Sector - Institutional holdings in the semiconductor sector increased to 11.01%, up by 1.67 percentage points from the previous quarter [22] - The recovery in downstream demand and low inventory levels are positive indicators for the sector [22] - Key companies such as SMIC, Chipone, and Weir shares have seen increased institutional investment [22] Consumer Electronics Sector - Institutional holdings in the consumer electronics sector decreased to 4.03%, down by 0.22 percentage points [31] - National subsidy policies are expected to boost sales of digital products, enhancing demand for upstream components [31] - Companies like Xiaomi and AAC Technologies have seen increased institutional holdings [31] Components Sector - Institutional holdings in the components sector decreased to 2.29%, down by 0.69 percentage points [3] - AI demand is expected to drive growth in the supply chain, with companies like Shengyi Technology and Dongshan Precision receiving more institutional investment [3] Optical and Optoelectronic Sector - Institutional holdings in this sector increased to 0.82%, up by 0.15 percentage points [3] - The demand for panels has remained strong, with prices rising in the first quarter [3] Electronic Chemicals Sector - Institutional holdings in the electronic chemicals sector increased to 0.49%, up by 0.11 percentage points [3] - The focus on domestic substitution continues to gain traction, with companies like Guanggang Gas and Dingsheng Technology receiving more institutional support [3]

[Table_Industry] 轻工制造 [Table_ReportDate] 2025 年 04 月 24 日 菲莫国际：HNB 稳健增长，口含烟延续高增 证券研究报告 行业研究 [Table_ReportType] 行业事项点评 | [Table_StockAndRank] 轻工制造 | | | --- | --- | | 投资评级 | 看好 | | 上次评级 | 看好 | 姜文镪 新消费行业首席分析师 执业编号：S1500524120004 邮箱：jiangwenqiang@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 菲莫国际：HNB 稳健增长，口含烟延续高增 [Table_ReportDate] 2025 年 04 月 24 日 本期内容提要: [Table_S [事件： Table_Summary 公司发布 ummary] ]2025 年一季报。2025Q1 收入为 93.01 亿美元（同比+5.8%， 经调整后同比+10.2%），其中新型烟草收入为 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of 23.343 billion yuan for 2024, representing a year-on-year growth of 18.79%. However, the net profit attributable to shareholders decreased by 14.78% to 560 million yuan. The non-GAAP net profit increased by 59.36% to 188 million yuan [1][2] - The core business segments showed strong growth, with smart education revenue increasing by 29.94% to 7.229 billion yuan, smart healthcare by 28.18% to 0.692 billion yuan, and the open platform by 31.33% to 5.172 billion yuan. New revenue growth points included smart automotive and enterprise AI solutions, which grew by 42.16% and 122.56% respectively [2] - The company has significantly increased its R&D investment, with total R&D expenses reaching 3.892 billion yuan in 2024, up 11.79% year-on-year. The operating cash flow reached a historical high of 2.495 billion yuan, a 613% increase, due to improved collection mechanisms [2] - The company has established three major AI commercialization systems, including industry applications, an open platform, and consumer products, which are driving business growth through a data-driven model [2][3] - The company’s deep learning model, X1, has achieved breakthroughs in reasoning and text generation, positioning it as a leading player in the AI field [5] Financial Summary - In 2024, the company achieved total revenue of 23.343 billion yuan, with a projected growth rate of 20.9% for 2025, reaching an estimated 28.212 billion yuan. The net profit attributable to shareholders is expected to recover to 775 million yuan in 2025, reflecting a growth rate of 38.4% [4] - The gross margin for 2024 was 42.63%, remaining stable compared to the previous year. The projected EPS for 2025 is 0.34 yuan, with corresponding P/E ratios of 134.52 for 2025, 105.33 for 2026, and 84.30 for 2027 [4][5]

蓄劲待时：华菱钢铁的"弹"与"韧" [Table_CoverStock] —华菱钢铁(000932)公司首次覆盖报告 证券研究报告 [Table_ReportDate] 2025 年 4 月 24 日 公司研究 [Table_ReportType] 公司首次覆盖报告 [Table_StockAndRank] 华菱钢铁(000932) 投资评级 买入 上次评级 [Table_Chart] -60% -40% -20% 0% 20% 40% 24/04 24/08 24/12 25/04 华菱钢铁 沪深300 资料来源：聚源，信达证券研发中心 [公司主要数据 Table_BaseData] | 收盘价（元） | 4.83 | | --- | --- | | 52 周内股价波动区间 | 5.78-3.39 | | (元) | | | 最近一月涨跌幅(％) | -10.08 | | 总股本(亿股) | 69.09 | | 流通 A 股比例(％) | 100% | | 总市值(亿元) | 326.78 | | 资料来源：聚源，信达证券研发中心 | | 左前明 能源行业首席分析师 执业编号：S1500518070001 ...

Investment Rating - The investment rating for the company is "Positive" [2] Core Insights - The company reported a Q1 2025 revenue of $9.301 billion, representing a year-on-year increase of 5.8%, and an adjusted year-on-year increase of 10.2%. The new tobacco revenue reached $3.895 billion, with a year-on-year growth of 15.0% and an adjusted growth of 20.4%. The new tobacco segment now accounts for 41.9% of total revenue, up 3.4 percentage points year-on-year, moving closer to the company's target of two-thirds by 2030 [2][3] - The net profit for Q1 2025 was $2.690 billion, reflecting a year-on-year increase of 25.2%, driven by product mix optimization and price increases in both new tobacco and traditional cigarettes [2] - The company’s HNB (Heated Not Burned) product sales reached 37.09 billion units in Q1 2025, marking an 11.9% year-on-year increase, with a global penetration rate of 5.7%, up 0.5 percentage points year-on-year [3] - In Japan, the adjusted sales growth for IQOS reached 9.3%, with a penetration rate of 32.4%, surpassing 50% market share in 13 major cities and 8 prefectures [3] - The company’s nicotine pouch sales were 5.3 billion units in Q1 2025, showing a year-on-year increase of 27.2%, with strong performance in both the U.S. and non-U.S. markets [4] - The company anticipates a global tobacco market decline of approximately 1% in 2025, while projecting a 12%-14% increase in new tobacco product sales, with HNB sales expected to grow by 10%-12% [4] - The company aims for IQOS to capture a 10% market share in the U.S. cigarette and HNB market by 2030 [4]

蓄劲待时：华菱钢铁的"弹"与"韧" [Table_CoverStock] —华菱钢铁(000932)公司首次覆盖报告 [Table_ReportDate] 2025 年 4 月 24 日 证券研究报告 公司研究 [Table_ReportType] 公司首次覆盖报告 [Table_StockAndRank] 华菱钢铁(000932) 投资评级 买入 上次评级 [Table_Chart] -60% -40% -20% 0% 20% 40% 24/04 24/08 24/12 25/04 华菱钢铁 沪深300 资料来源：聚源，信达证券研发中心 [公司主要数据 Table_BaseData] | 收盘价（元） | 4.83 | | --- | --- | | 52 周内股价波动区间 | 5.78-3.39 | | (元) | | | 最近一月涨跌幅(％) | -10.08 | | 总股本(亿股) | 69.09 | | 流通 A 股比例(％) | 100% | | 总市值(亿元) | 326.78 | | 资料来源：聚源，信达证券研发中心 | | 左前明 能源行业首席分析师 执业编号：S1500518070001 ...